Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24819074 | 0.97 | — | — | |
| SCHEMBL19096435 | 0.92 | — | — | |
| SCHEMBL290901 | 0.86 | — | — | |
| SCHEMBL15140889 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL290344 | 0.83 | — | — | |
| SCHEMBL1431683 | 0.79 | USP2 (0.37) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL2154595 | 0.78 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL2154404 | 0.78 | ALDH1A1 (0.43) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14744105 | 0.75 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1192219 | 0.75 | AOC2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947663-A | Synthesis method of tranexamic acid | 上海巽田科技股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | claimed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | claimed |
| CN-116947663-A | Synthesis method of tranexamic acid | 上海巽田科技股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | disclosed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | disclosed |
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2151432-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| CN-1121384-C | Penicilliamine amide derivatives | MITSUBISHI CHEM CORP (JP) | 2003-09-17 | — | — | CN | disclosed |
| CN-1197454-A | Penicilliamine amide derivatives | MITSUBISHI CHEM CORP (JP) | 1998-10-28 | — | — | CN | disclosed |
| CN-1121068-A | Prolinamide derivatives | MITSUBISHI CHEM CORP (JP) | 1996-04-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | ALDH1A1 2862/4885USP2 4445/4885LMNA 2362/4885 |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | ALDH1A1 2019/4885USP2 4164/4885LMNA 2785/4885 |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4238/4885USP2 1141/4885LMNA 2720/4885 |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | ALDH1A1 3021/4885USP2 2868/4885LMNA 3845/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | ALDH1A1 2862/4885USP2 4445/4885LMNA 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.